Related Experiment Video
Updated: Feb 22, 2026
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation
Rick A Nishimura1, Hubert Seggewiss2, Hartzell V Schaff2
1From the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (R.A.N.); Medizinische Klinik 1, Leopoldina Krankenhaus, Schweinfurt, Germany (H.S.); and Department of Cardiovascular Surgery, Rochester, MN (H.V.S.). rnishimura@mayo.edu.
Insights
Hypertrophic cardiomyopathy patients unresponsive to medication can undergo septal reduction therapy. Both surgical septal myectomy and alcohol septal ablation offer effective obstruction relief, with outcomes depending on operator expertise and patient factors.
Area of Science:
- Cardiology
- Genetics
- Medical Therapy
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disorder causing myocardial hypertrophy.
- It often leads to dynamic left ventricular outflow tract obstruction, causing symptoms like dyspnea, angina, and syncope.
- Medical therapy with beta-blockers and calcium antagonists is the initial treatment for symptomatic obstruction.
Purpose of the Study:
- To review septal reduction therapy options for HCM patients with persistent, severe symptoms unresponsive to medical management.
- To compare the efficacy and outcomes of surgical septal myectomy and alcohol septal ablation.
- To highlight factors influencing treatment decisions in hypertrophic cardiomyopathy.
Main Methods:
- Review of existing literature on septal reduction therapies for hypertrophic cardiomyopathy.
- Comparison of surgical septal myectomy and alcohol septal ablation techniques.
- Analysis of patient outcomes, including obstruction relief, symptom improvement, and procedural risks.
Main Results:
- Surgical septal myectomy, performed by experienced operators in high-volume centers, provides >90% obstruction relief and symptom improvement with <1% perioperative mortality.
- Alcohol septal ablation is less invasive and offers comparable hemodynamic and clinical results in many patients.
- Alcohol septal ablation's success depends on septal artery anatomy, and some patients, especially younger ones with severe hypertrophy, may not achieve complete symptom relief.
Conclusions:
- Septal reduction therapy, including surgical septal myectomy and alcohol septal ablation, is a viable option for severe, medically refractory obstructive hypertrophic cardiomyopathy.
- Both procedures are highly operator-dependent, and treatment selection should consider patient preference, operator experience, and institutional expertise.
- While both methods are effective, patient selection and procedural success are influenced by individual anatomy and operator skill.
Abstract:
Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a >90% relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is <1%. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.
More Related Videos
07:02Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:26Mitral Stenosis III: Medical Management
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:30Cardiomyopathy II: Dilated Cardiomyopathy